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A signiﬁcant proportion of disease-causing mutations affect precursor-mRNA splicing, inducing skipping of
the exon from the mature transcript. Using F9 exon 5, CFTR exon 12 and SMN2 exon 7 models, we character-
ized natural mutations associated to exon skipping in Haemophilia B, cystic ﬁbrosis and spinal muscular
atrophy (SMA), respectively, and the therapeutic splicing rescue by using U1 small nuclear RNA (snRNA).
In minigene expression systems, loading of U1 snRNA by complementarity to the normal or mutated
donor splice sites (5′ss) corrected the exon skipping caused by mutations at the polypyrimidine tract of
the acceptor splice site, at the consensus 5′ss or at exonic regulatory elements. To improve speciﬁcity
and reduce potential off-target effects, we developed U1 snRNA variants targeting non-conserved intronic
sequences downstream of the 5′ss. For each gene system, we identiﬁed an exon-speciﬁc U1 snRNA
(ExSpeU1) able to rescue splicing impaired by the different types of mutations. Through splicing-competent
cDNA constructs, we demonstrated that the ExSpeU1-mediated splicing correction of several F9 mutations
results in complete restoration of secreted functional factor IX levels. Furthermore, two ExSpeU1s for SMA
improved SMN exon 7 splicing in the chromosomal context of normal cells. We propose ExSpeU1s as a
novel therapeutic strategy to correct, in several human disorders, different types of splicing mutations asso-
ciated with defective exon deﬁnition.
INTRODUCTION
Splicing errors represent a signiﬁcant amount of disease-causing
mutations. Considering only changes at canonical splice sites,
 15% of mutations were originally estimated to induce aberrant
splicing (1) and similar frequencies are recorded in human
disease databases [for example, 12% in cystic ﬁbrosis (CF)
and 10% in coagulation FIX (FIX) deﬁciency (Haemophilia
B)]. However, the occurrence of splicing defects is signiﬁcantly
increased ( 50%) when genomic variants are systematically
evaluated for their effect on precursor-mRNA (pre-mRNA) pro-
cessing (2,3). This unexpected effect is largely due to mutations
located in non-canonical regulatory elements and highlights the
difﬁculty in correctly predicting the consequence of genomic
variants on pre-mRNA splicing (4–8).
To correctly identify the exonic sequences from the larger
non-coding introns, the splicing machinery recognizes
several cis-acting elements on the nascent transcripts
(9,10). The core elements required for splicing are moderate-
ly conserved and consist of the classical or canonical 5′ and
3′ splice sites (named also donor and acceptor sites) and
include the polypyrimidine tract as well as the branch site
near the 3′ss. The consensus motif of the 5′ss is made of
nine-nucleotide sequence, CAG/GURAGU where R is a
purine and, with the exception of the nearly obligate GU di-
nucleotide, the other positions are quite degenerated. Recog-
nition of the exon requires also splicing regulatory elements
that are classiﬁed, depending on their location and effect on
splicing, as exonic/intronic splicing enhancers (ESE and
ISE), exonic/intronic splicing silencers (ESS and ISS)
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(CERES) (7). The exonic elements are composed by
largely degenerated sequences, overlap with the coding cap-
acity and interact with splicing factors with a positive (SR
proteins) or negative (hnRNPs) effect on the exon recogni-
tion. In general, factors associated to the splice sites and
to the exonic splicing regulatory elements promote a
network of interactions across the exon. As a result, the
ﬁnal outcome of a splicing decision depends on the equilib-
rium between multiple positive and negative interactions
over the exon in a process called exon deﬁnition (11).
Aberrant exon skipping is a common splicing defect
caused by disruption of the network of interactions that
deﬁne the exon. It results from mutations at the consensus
donor or acceptor sites, at the polypyrimidine tract or in
the exonic regulatory elements. In general, mutations at the
consensus donor site reduce the complementarity with the
U1 small nuclear RNA (snRNA) (see below), substitutions
at the 3′ss polypyrimidine tract interfere with the complexes
assembled on the 3′ss and exonic mutations affect exonic
regulatory elements.
An early event in exon deﬁnition is the recognition of the
donor site by the U1 snRNP (small nuclear RiboNuclearParti-
cle). U1 snRNP is composed by a 164 bp long U1 snRNA
associated to several protein factors. To initiate splicing, the
5′ end of the U1 snRNA interacts by complementarity with
the moderately conserved sequence of the 5′ss. Interestingly,
 40, 22 and 5% of normal 5′ss contains, respectively, two,
three or four mismatches toward the U1 snRNA (12). U1
snRNAs with a modiﬁed 5′ tail that base pair exactly to the
mutant donor sites have been used to correct 5′ss mutation
(13–19). For example, we previously showed that a U1
snRNA complementary to the +5G/A mutant of the intron 7
donor splice site of coagulation F7 rescued splicing and
protein biosynthesis and function in minigene systems
(14,15). However, this correction approach appears to be
limited to single mutations and, through the ability of modiﬁed
U1 snRNAs to target other donor sites, it can potentially inter-
fere with splicing of other pre-mRNAs.
Here, to study the effect of mutations on splicing and iden-
tify a correction strategy on an exon basis, we considered three
genes relevant in human pathology, the coagulation F9, the
Cystic Fibrosis Transmembrane Regulator (CFTR) and the
SMN2 (Survival of Motoneuron 2), whose mutations are asso-
ciated to coagulation factor IX (Haemophilia B), CF and
spinal muscular atrophy (SMA), respectively. Expression ana-
lysis of several substitutions at the donor splice sites (in F9
exon 5 and CFTR exon 12), at the polypyrimidine tract (in
F9 exon 5) and at exonic regulatory elements (in CFTR
exon 12 and in SMN2 exon 7), indicated their ability to
cause aberrant splicing and particularly exon skipping. Screen-
ing of U1 snRNAs binding at non-conserved intronic
sequences downstream the exon identiﬁed for each case an
unique exon-speciﬁc U1 snRNA (ExSpeU1) able to correct
different types of mutations. In SMN, two ExSpeU1-corrected
exon 7 skipping in the normal chromosomal context. More-
over, in a FIX splicing-competent expression system, an
ExSpeU1 restored, for several mutations, protein secretion
and procoagulant function to an extent that, if achieved in
vivo, would be therapeutic.
RESULTS
Effects of F9 exon 5 and CFTR exon 12 mutations
on pre-mRNA splicing
We evaluated nine different natural mutations associated with
Haemophilia B deﬁciency (Fig. 1A) and seven mutations asso-
ciated to CF (Fig. 1C). The list of the mutations analysed and
their associated clinical phenotype are shown in Supplemen-
tary Material, Table S1. Mutations are numbered according
to their position relative to the donor or acceptor site. The
mutations in the F9 gene consists of two T to G transversions
at the 3′ss polypyrimidine tract and seven substitutions at or
near the 5′ss of exon 5. In the CFTR exon 12, we studied
ﬁve donor-site substitutions and, as models for exonic muta-
tions that affect splicing, two codon changes (A566T and
Y577Y) located in the previously reported CERES element
(7) (Supplementary Material, Table S1). To test their effect
on splicing, the substitutions were inserted in appropriate
minigenes followed by analysis of the splicing pattern in eu-
karyotic cells. For F9 exon 5, we prepared a novel minigene,
whereas the CFTR exon 12 minigene has been previously
described and extensively validated (7,8,20). Normal F9 ex
5 wt minigene showed that the exon was not completely
included ( 85%) in the mature mRNA (Fig. 1B, lane 3).
This pattern of splicing is entirely consistent with the in vivo
splicing pattern of the F9 gene in human liver, where  90%
of the exon is included (Supplementary Material, Fig. S1).
The appreciable level of alternative splicing indicates that
the exon 5 is poorly deﬁned, very likely because of the pres-
ence of a weak 5′ss. In fact, it differs signiﬁcantly from the
consensus donor site at positions 3, 5 and 6, with a C, a U
and an A, respectively (Supplementary Material, Fig. S2). Ex-
pression studies of the F9 ex 5 mutations revealed that the ma-
jority of them induced aberrant pre-mRNA processing
(Fig. 1A). The 28 and 29 transversions of the polypyrimi-
dine tract and the mutations at the consensus 5′ss at positions
22, 21, +1 and +2 induced complete exon skipping. On the
other hand, all mutations in CFTR exon 12, either located at
the donor sites (in position 21, +3 and +5) or in the exon
(A566T and Y577Y), induced exon skipping (Fig. 1D). In is
worth noting that the A566T and Y577Y exonic variants
affect exonic splicing regulatory elements (7), which are im-
portant for correct exon deﬁnition. Thus, in two model
systems, several natural mutations either at the splice sites
or at exonic regulatory elements induce exon skipping.
U1 snRNAs complementary to the mutant 5′ss rescue
some defective donor sites
We initially focused on mutations at donor sites, which reduce
their complementarity to the 5′ tail of the U1 snRNA. To
understand for each mutation the role of U1 snRNA in exon
recognition, we prepared U1 snRNAs expression plasmids
with compensatory changes that completely restore base-
pairing with the wt or mutant 5′ss (Supplementary Material,
Figs S2 and S3). These U1 snRNAs were cotransfected with
the corresponding minigene variants followed by the analysis
of the splicing pattern.
Cotransfection of U1FIXwt with the ex5 wt minigene
improved the exon recognition inducing complete inclusion
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onymous changes at position 22 showed a remarkable in-
crease in the percentage of exon inclusion after
cotransfection of the corresponding complementary U1
snRNAs, with a negligible presence of aberrant transcripts
(Fig. 2A, lanes 4–9). On the contrary, the splicing pattern of
the other FIX mutations 21T, +1A and +2C was not affected
by the corresponding complementary U1 snRNAs.
Minigene experiments with the CFTR exon 12 showed that
all mutations were rescued by the corresponding complemen-
tarity U1 snRNAs. Whereas the 21T, +3C and +5A were
slightly enhanced (Fig. 2B), the severe splicing defects
caused by 21A and +3G mutations were efﬁciently corrected
by the complementary U1 snRNAs, reaching  75 and  95%
of exon inclusion. Cotransfection of U1 CFwt with the CFex12
wt also improved the splicing pattern (Fig. 2B, lane 3).
Figure 1. Effect of natural mutations on F9 exon 5 and CFTR exon 12
pre-mRNA splicing. (A and C) Schematic representation of the central
region of the pFIX exon 5 and pCFex12 minigenes, respectively. Exonic
sequences are boxed, introns are lines and the arrows represent primers for
PCR ampliﬁcation. The position of genomic variants relative to the splice
sites is indicated. Exonic and intronic sequences are in upper and lower
case, respectively. (B) Analysis of pFIX exon 5-spliced transcripts. HeLa
cells were transfected with pFIXex5 wt or mutant minigenes and splicing
pattern evaluated by RT–PCR. Ampliﬁed products were resolved on a 2%
agarose gel. The identity of the bands is indicated on the right of the panel.
M is the molecular 1 Kb marker. Lower panel shows the quantiﬁcation of
the percentage exon 5 inclusion (mean+SD of three independent experiments
done in duplicate). (D) Analysis of pCF exon 12 spliced transcripts. HeLa cells
were transfected with pFIX ex12 wt or mutant minigenes and splicing pattern
evaluated by RT–PCR. Ampliﬁed products were resolved on a 2% agarose
gel. Lower panel shows the quantiﬁcation of the percentage exon 12 inclusion
(mean+SD of three independent experiments done in duplicate).
Figure 2. Effect of increased complementarity of U1 snRNAs to normal and
mutated donor splice site on pre-mRNA splicing. (A) Effect of complementary
U1 snRNA to the F9 exon 5 5′ss. The upper panel shows the analysis of
spliced transcripts. Minigenes were transfected in HeLa cells with the empty
vector (lanes 1, 4, 6, 8, 10, 12, 14) or with modiﬁed U1s (lanes 3, 5, 7, 9,
11, 13, 15) and splicing pattern evaluated by RT–PCR. Ampliﬁed products
were resolved on a 2% agarose gel. The identity of the U1 snRNAs is
shown in Supplementary Material, Figure S2. Lower panel is the quantiﬁcation
of exon 5 splicing pattern after co-transfection with modiﬁed U1 snRNAs.
Data are expressed as means+SD of three independent experiments done
in duplicate. (B) Effect of complementary U1 snRNAs to the CFTR exon
12 5′ss. Minigenes were transfected in HeLa cells with the empty vector
(lanes 4, 6, 8) or with modiﬁed U1s (lanes 3, 5, 7, 9) and the splicing
pattern evaluated by RT–PCR. Ampliﬁed products were resolved on a 2%
agarose gel. The identity of the U1 snRNAs is shown in Supplementary Ma-
terial, Figure S2. Lower panel is the quantiﬁcation of exon 12 splicing pattern.
Data are expressed as means+SD of three independent experiments done in
duplicate.
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iants in F9 exon 5 and the donor 5′ss mutations in CFTR
exon 12 do not completely disrupt the 5′ss function. They
produce a defective donor site, whose recognition by comple-
mentary U1 snRNA variants recovers correct exon inclusion.
U1 snRNAs complementary to intronic sequences
downstream of the 5′ss correct aberrant splicing
To promote exon deﬁnition, U1 snRNP does not necessarily
have to perfectly bind at the 5′ss. Some atypical 5′ss are recog-
nized by U1 snRNA shifted by one nucleotide (21) and U1
snRNA complementary to downstream intronic sequences
were originally reported to promote exon inclusion in model
gene system (22,23). Thus, we tested the effect of U1 snRNA-
binding downstream mutant CFTR exon 12 and F9 exon 5. For
this purpose, we prepared different U1 snRNAs, whose 5′ tails
were modiﬁed to base pair at variable distance downstream of
the 5′ss of F9 exon 5 and CFTR exon 12 (Fig. 3). This ap-
proach was also extended to the extensively investigated
SMN2 exon 7, where a weak constitutive 5′ss and a
synonymous exonic substitution are associated to exon skip-
ping (24–26). In F9, we systematically screened U1
snRNAs from position 27 till position 63 relative to the
donor site junction and the analysis was performed on the
ex5 22C mutant minigene. As shown in Figure 3A, all U1
snRNAs tested reduced exon 5 skipping, indicating their posi-
tive effect on exon deﬁnition. In particular ﬁx 1, ﬁx 9 and ﬁx
10 U1 snRNAs showed the strongest effect with a nearly com-
plete rescue of aberrant splicing. In CFTR exon 12, only the
U1 snRNA variant cf11 induced a signiﬁcant (70%) rescue
of the splicing pattern in the +3G mutant (Fig. 3D). The
other U1 snRNAs had a modest effect (cf1 and cf9) or no
effect (cf15 and cf33) on splicing (Fig. 3D). In the SMN2
minigene,  20% of exon 7 is included in the ﬁnal transcript,
whereas cotransfection of sm2, sm17 and sm21 resulted in
.80% of exon inclusion (Fig. 4B).
These results in three different gene systems indicate that
U1 snRNAs binding downstream the 5′ss corrected exon skip-
ping caused by defective 5′ss.
SMN-speciﬁc U1 snRNAs rescue exon 7 splicing
in normal cells
To study the effect of different ExSpeU1s in the chromosomal
context, we focussed on SMN exon 7. Normal individuals
have two SMN copies, SMN1 and SMN2, that mainly differ
for a synonymous substitution in exon 7. This substitution
induces SMN2 exon 7 skipping and because the majority of
SMA patients lack SMN1, its splicing correction is at the
basis of several therapeutic attempts (27,28). To evaluate the
potential therapeutic effect of SMN-speciﬁc U1s in SMA,
we transfected sm17 and sm21 in HEK293 cells and evaluated
the endogenous pattern of splicing. Semiquantitative analysis
of splicing isoforms showed that sm17 and sm21 induced a
signiﬁcant increase in the percentage of SMN exon 7 inclu-
sion. In particular, transfection of the two ExSpeU1s increased
the percentage of SMN2 exon 7 from  40 to  70% (Fig. 5).
A unique exon-speciﬁc U1 snRNA can rescue splicing
of defective splice site mutants and exonic variants
WesubsequentlytestedtheeffectofthemostactiveU1snRNAs
(ﬁx9 for FIX and cf11 for CFTR), named exon-speciﬁc U1
snRNAs (ExSpeU1), on all splicing mutations. In F9 exon 5,
ﬁx9 ExSpeU1 completely rescued the defective donor sites of
the three synonymous mutations in position 22 (Fig. 6A,
lanes 5–10). At variance, the 21T, +1A and +2C 5′ss muta-
tions, not corrected by loading the U1 snRNA directly on the
Figure 3. Identiﬁcation of ExSpeU1s in F9 exon 5 and CFTR exon 12. (A and
C) Schematic representation of binding sites of the ExSpeU1s in F9 exon 5
and CFTR exon 12, respectively. Donor site and downstream intronic region
are shown and exonic and intronic sequences are in upper and lower case, re-
spectively. Lines correspond to the target-binding sequences of ExSpeU1s U1
snRNAs on the nascent pre-mRNA. (B) Analysis of F9 exon 5-spliced tran-
scripts. The FIXex5-2C mutant minigene was transfected in HeLa cells
alone (lane 1), with the empty vector (lane 2), or with plasmids encoding
for the different ExSpeU1s. The pattern of splicing was evaluated by
RT–PCR and ampliﬁed products were resolved on a 2% agarose gel. Lower
panel is the quantiﬁcation of exon 5 splicing pattern. (D) Analysis of CFTR
exon 12-spliced transcripts. The mutant ex12 + 3G minigene was transfected
in HeLa cells alone (lane 1), with the empty vector (lane 2), or with plasmids
encoding for the ExSpeU1s. The pattern of splicing was evaluated by
RT–PCR and ampliﬁed products were resolved on a 2% agarose gel. Lower
panel is the quantiﬁcation of exon 5 splicing pattern.
2392 Human Molecular Genetics, 2012, Vol. 21, No. 11donor site (Fig. 2A), were also not inﬂuenced by ExSpeU1 ﬁx9
(Fig. 6A, lanes 11–16). Interestingly, cotransfection of
ExSpeU1 ﬁx9 induced nearly complete exon inclusion of the
two 28G and 29G intronic variants of the polypyrimidine
tract (Fig. 5A, lanes 1–4). In CFTR exon 12, ExSpeU1 cf11
rescued all 5′ss mutations with different efﬁciency. After
ExSpeU1 cf11 cotransfection, the +3G mutation showed
 85%ofexoninclusion(Fig.6B);thepercentageofexoninclu-
sion in 21A, +3C and +5A increased to  50%, whereas in
21T it improved to  20% (Fig.6B). Intriguingly, we observed
complete splicing correction by ExSpeU1 cf11 of the two
exonic A566T and Y577Y mutations (Fig. 6B, lanes 1–4). Se-
quencing of ExSpeU1-induced products showed correct usage
of the normal intron–exon junction and no activation of
cryptic splice sites. To clarify if the enhancing effect is speciﬁc
for the U1 snRNA particle, we inserted the tail of two active
ExSpeU1s,ﬁx10andcf11,intheU7snRNA.U7isnotinvolved
in splicing and a modiﬁed version has been extensively used to
express antisense RNA sequences (29–35). The resulting
U7 ﬁx10 and U7 cf11 were cotransfected with 28G, 22T
mutants and +3G and Y577Y, respectively. In contrast to the
ExSpeU1s, the corresponding U7s had no effect (Supplemen-
tary Material, Fig. S4), suggesting that U1 snRNP-speciﬁc
proteins are required for splicing rescue and that ExSpeU1s
are not just targeting intronic sequences with silencer function.
Altogether, these data indicate that recruitment of ExSpeU1
by complementarity on intronic sequences downstream of the
exon corrects multiple splicing mutations located either at 5′
or 3′ splice sites or in exonic regulatory elements. This pro-
vides a novel therapeutic strategy exploiting a unique
ExSpeU1 to correct a panel of splicing defects.
Rescue of splicing by the F9 exon5-speciﬁc U1 snRNA
results in FIX biosynthesis and coagulant activity
To establish whether the ExSpeU1-mediated correction of
splicing of the different mutants result in a consistent rescue
Figure 4. Identiﬁcation of ExSpeU1s in SMN2 exon 7. (A) Schematic repre-
sentation of binding sites of the ExSpeU1s in SMN2 exon 7. Donor site and
downstream intronic region are shown and exonic and intronic sequences
are in upper and lower case, respectively. Lines correspond to the target-
binding sequences of ExSpeU1s on the nascent pre-mRNA. (B) Analysis of
SMN2 exon 7 spliced transcripts. The pCI-SMN2 minigene was transfected
in HeLa cells alone (lane 1), with the U1wt (lane 2), or with plasmids encoding
for ExSpeU1s. The pattern of splicing was evaluated by RT–PCR and ampli-
ﬁed products were resolved on a 2% agarose gel. Lower panel is the quantiﬁ-
cation of SMN2 exon 7 splicing pattern. Data are the means+SD of three
experiments done in duplicate.
Figure 5. SMN exon 7 splicing correction mediated by sm17 and sm21
ExSpeU1s in normal cells. The upper panel shows a representative experiment
in which the ﬂuorescently labelled RT–PCR ampliﬁed fragments were sepa-
rated on denaturing capillary electrophoresis. HEK393 cells were transfected
with the indicated ExSpeU1s and ampliﬁed fragments were digested with
DdeI to obtain SMN1 and SMN2 exon 7 inclusion (FL) and exclusion (D7)
fragments. The size of the fragments is indicated. Lower panel shows the
percentage of SMN1 and SMN2 exon 7 inclusion in ExSpeU1-treated
and -untreated cells and data are expressed as means+SD of three independ-
ent experiments done in duplicate. Transfection efﬁciency in the different
experiments was 75–85%.
Human Molecular Genetics, 2012, Vol. 21, No. 11 2393of protein biosynthesis and function, we took advantage of the
FIX model. FIX is a serine protease secreted from cells that
can be ﬁnely monitored by protein and functional assays.
The splicing mutations corrected by the ExSpeU1 ﬁx9 (the
three 22 variants at the 5′ss and the two transversions at the
polypyrimidine tract) were tested in a splicing-competent
cDNA minigene context (pBsKFIX) (Fig. 7A). In this mini-
gene, exon 5 was inserted in FIX cDNA transcript along
with part of its intronic sequences in a manner that the correc-
tion of exon skipping produces a normal transcript with secre-
tion of a functional protein (Fig. 7A). The pBsKFIX exon 5 wt
and mutant minigenes were expressed in BHK cells with or
without the modiﬁed U1 snRNAs complementary to the F9
donor site (U1FIXwt) or to the downstream intronic sequence
(ﬁx9).
Probably caused by the pBsKFIX minigene context, this
construct showed exon 5 inclusion in  10% of the transcripts
(Fig. 7, lane 1), while experiments with the pTB minigene
(Fig. 1) and in vivo (Supplementary Material, Fig. S3)
showed a  85% inclusion. In spite of this inefﬁcient exon 5
recognition, the secreted FIX levels in the conditioned
medium were appreciable by ELISA (13+1 ng/ml), western
blotting (Fig. 7C) and coagulation assays (Fig. 7D). In particu-
lar, western blotting revealed the presence of a band corre-
sponding to the full-length FIX form ( 60 kDa), which
migrated as plasma-derived FIX. In addition, a band corre-
sponding to a smaller size FIX variant ( 51 kDa) was also
clearly detectable. This arises from translation of the in
frame FIX mRNA form lacking exon 5 (Fig. 7C), leading to
a FIX molecule lacking 43 amino acids of the second epider-
mal growth factor like domain 2 (EGF2). Notably, the mRNA
splicing and western blot patterns showed remarkably differ-
ent relative amount of the two isoforms, with the aberrant
form predominating at the mRNA (Fig. 7B) but not at the
protein (Fig. 7C) level, a ﬁnding compatible with inefﬁcient
biosynthesis of the protein without the EGF2 domain.
Figure 6. Splicing correction mediated by ﬁx9 and cf11 U1 ExSpeU1s on
natural mutations. (A) HeLa cells were transfected with the indicated FIX
exon 5 mutant minigenes alone (even lanes) or along with ﬁx9 U1
ExSpeU1 (odd lanes). Splicing pattern was evaluated by RT–PCR and amp-
liﬁed products were resolved on a 2% agarose gel. Ms is the molecular
1 Kb plus marker. Lower panel shows the quantiﬁcation of exon 5 splicing
pattern. Percentage of exon inclusion is expressed as means+SD of three
experiments done in duplicate. (B) HeLa cells were transfected with the indi-
cated CFTR exon 12 mutant minigenes alone (even lanes) or along with cf11
ExSpeU1 (odd lanes). Splicing pattern was evaluated by RT–PCR and amp-
liﬁed products were resolved on a 2% agarose gel. Lower panel shows the
quantiﬁcation of exon 12 splicing pattern. Percentage of exon inclusion is
expressed as means+SD of three experiments done in duplicate.
Figure 7. Rescue of splicing and FIX protein function by ExSpeU1. (A) Sche-
matic representation of the pBsK-FIX minigene. Exonic sequences are boxed,
introns are lines, the arrows represent primers for PCR ampliﬁcation and the
dotted lines indicate the two possible exon 5 alternative splicing events. The
position of the ATG and TAA codons is indicated. The minigene is not
drawn in scale. (B) Analysis of pBsK-FIX exon 5 spliced transcripts.
pBsK-FIX exon 5 normal and mutant minigenes were transfected in BHK
cells alone or with the indicated ExSpeU1s. The splicing pattern was evaluated
by RT–PCR and ampliﬁed products were resolved on a 2% agarose gel. M is
the molecular 1 Kb marker. Lower panel shows the quantiﬁcation of the per-
centage exon 5 inclusion. Data are expressed as means+SD of three inde-
pendent experiments done in duplicate. (C) Western blotting of FIX in the
BHK conditioned medium. PNP is pooled normal plasma. (D) FIX coagulant
activity in the BHK conditioned medium. Data are expressed as means+SD
of three experiments done in duplicate.
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complete skipping of the exon (Fig. 7B, lanes 2, 5, 8, 11, 14),
and cotransfection of either U1FIXwt or ﬁx9 ExSpeU1
induced a complete rescue of the splicing pattern. In all ﬁve
mutants, the percentage of exon inclusion increased to level
above 75% (Fig. 7B). The extent of splicing rescue mediated
by these U1 snRNAs was remarkable, taking into account
the inefﬁcient exon 5 recognition in this context. Results
from investigations at the protein level in the conditioned
medium were consistent with those from splicing assays.
The expression of the ﬁve mutants resulted in secretion of
deleted FIX proteins (Fig. 7C), which did not display any ap-
preciable coagulant activity (Fig. 7D). At variance,
co-expression of variants with either U1FIXwt or ﬁx9
ExSpeU1 induced the exclusive synthesis of the full-length
FIX (Fig. 7C). This was paralleled by a complete rescue of
FIX activity (Fig. 7D), which for most variants was higher
than that measured for the pBsKFIX wt construct.
DISCUSSION
In this study, we provide a novel strategy to correct different
types of natural splicing mutations using exon speciﬁc U1
snRNAs (ExSpeU1). ExSpeU1s bind by complementarity
to intronic sequences downstream of the exon and rescue
different types of splicing defects associated to exon skip-
ping. ExSpeU1s are active on several 5′ss mutations in
CFTR exon 12 and F9 exon 5, on two transversions at the
polypyrimidine tract in F9 exon 5, on two exonic substitu-
tions in CFTR exon 12 and on defective SMN2 exon 7 spli-
cing (also due to an exonic variant). In this latter case,
ExSpeU1 rescued SMN2 exon 7 splicing directly in the
chromosomal context of normal cells, providing a new thera-
peutic strategy for SMA. On the other hand, in the model of
Haemophilia B, a unique ExSpeU1 induced complete spli-
cing correction of ﬁve different F9 mutations, thus resulting
in a complete rescue of protein biosynthesis and coagulation
activity.
A limited number of studies have explored the role and po-
tential therapeutic effect of U1 snRNAs on splicing correction
of donor site mutations (13–19). In all cases, the modiﬁed tails
of U1 snRNA have few nucleotide changes in comparison to
the WT sequences and base pair exactly to the mutant donor
sites. Thus, their therapeutic effect is restricted to each muta-
tion and the potential complementarity of these modiﬁed U1
snRNAs to other normal 5′ss might affect splicing of other
exons, in particular those alternatively spliced. The
ExSpeU1s we have developed here, which bind to non-
conserved intronic sequences, have two major advantages,
(i) they do not interact directly with normal 5′ss and (ii)
correct different types of splicing defects associated to exon
skipping. The mutations rescued by ExSpeU1s affect three dif-
ferent splicing regulatory elements important for exon recog-
nition: the 5′ss, the polypyrimidine tract of the 3′ss and the
exonic splicing regulatory sequences. To our knowledge, this
is the ﬁrst time that an U1 snRNA variant is shown to
correct exon skipping due to polypyrimidine tract and
exonic mutants. SMN2 is a paradigmatic example of exon
skipping caused by a synonymous variant in an exonic
regulatory element and its correction is at the basis of
several therapeutic attempts in SMA (27,28).
Compared with classical gene replacement therapies,
ExSpeU1-mediated rescue has a number of additional advan-
tages and stimulating perspectives. The direct splicing correc-
tion maintains the regulation of the gene expression in the
correct cell-speciﬁc chromosomal context under the control
of endogenous transcription and pre-mRNA processing regula-
tory elements. The short length of the ExSpeU1s cassette
( 500 bp) can also be useful in gene therapy of splicing muta-
tions in large genes such as CFTR and F8, whose full-length
transcript can represent a limiting step for their insertion in
viral vectors such as AAV. On the other hand, to achieve
the optimal therapeutic rescue, the expression level could be
modulated in vivo by varying the number of ExSpeU1 cassette
in the viral vector. In the case of dominant-negative mutations
where the replacement therapy is not feasible, the splicing cor-
rection mediated by ExSpeU1 will act directly reducing the
amount of the mutated toxic protein. Moreover, binding of
the ExSpeU1s to intronic sequences, which are not conserved,
will signiﬁcantly reduce the possibility of off-target events.
Although binding of ExSpeU1s to unrelated sequences not dir-
ectly involved in splicing might have an effect on other
pre-mRNA processing steps (36), our result indicate that it
will be possible to design ExSpeU1s with improved speciﬁcity
by inserting subtle changes in sequence target and/or length.
For example, ExSpeU1s sm17 and sm21 in SMN2 (Fig. 3B)
or ﬁx9, ﬁx10 and ﬁx13 in F9 exon 5 (Fig. 3B) bind at
nearby or overlapping intronic sequences and are functionally
active. Future studies in cellular and animal models will be
required to address this point.
According to the classical exon deﬁnition model, a network
of interactions across the exon put in contact the splicing com-
plexes assembled on the splice sites (11,19,37). This includes
the recognition of the 5′ss by the U1 snRNP, binding of
U2AFs to the polypyrimidine tract and identiﬁcation of
exonic splicing regulatory elements by SR proteins. The muta-
tions we have analysed here affect differently these regulatory
elements and probably block splicing at the ﬁrst step when the
exon has to be recognized co-transcriptionally. At this stage,
recruitment of U1 snRNA at the 5′ss or at downstream
sequences by means of ExSpeU1s can rescue the different
defects. This occurs not only for mutations at the consensus
5′ss that directly interfere with U1 snRNA binding but also
for mutations located at distance from the donor site in the
polypyrimidine tract or in exonic regulatory elements. In
these cases, ExSpeU1s probably compensate the missing inter-
actions and facilitate the formation of the correct network of
splicing factors over the exon.
Interestingly, the two ExSpeU1s for SMN2 (sm17 and
sm21) are partially complementary to a previously reported in-
tronic splicing silencer, which binds to the negative splicing
factor hnRNPA1 (38). Targeting this ISS with antisense oligo-
nucleotides resulted in inclusion of SMN2 exon 7 in model
minigenes and in cellular systems (39) and was recently
shown to improve the phenotype in a SMA mouse model
(27). Thus, it is possible that ExSpeU1s facilitates recruitment
of the splicing machinery on the exon interfering with intronic
splicing regulatory sequences located downstream the donor
site. However, this mechanism seems unlikely for F9 exon 5
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target intronic sequences had no effect on splicing (Supple-
mentary Material, Fig. S4). It is possible that ExSpeU1 acts
at different levels depending on the architecture and relative
strength of splicing regulatory elements in each exon. More
in general, ExSpeU1s-mediated induction of exon inclusion
could be used to regulate the synthesis of speciﬁc alternatively
spliced isoforms for therapeutic purposes. For example, thera-
peutic induction of speciﬁc alternative splicing isoforms affect
tumour progression (40), angiogenesis (41,42) or aging (43),
and modiﬁed U1 snRNAs have been recently used to
promote splicing to inhibit HIV replication (44).
Even if the disease-causing splicing mutations here investi-
gated have a comparable effect on mature transcript, they
behave differently regarding their sensitivity to ExSpeU1-
mediated correction. The 21T +1T and +2C mutations in
F9 exon 5 did not respond to the ExSpeU1 ﬁx9, whereas the
5′ss mutations in CFTR exon 12 showed a variable response
to cf11 ExSpeU1: in this case, the rescue efﬁciency was
optimal for the +3G, intermediate for the 21A, +3C and
+5A and low for the 21T (Fig. 5). As we have previously
suggested (19), the different rescue efﬁciency to ExSpeU1
indicates that donor site mutations are mechanistically differ-
ent. Interestingly, mutations that respond to ExSpeU1 (Fig. 2)
were also sensitive to U1 snRNA complementary to the
mutated 5′ss sequence (Fig. 5), suggesting a common effect
of U1 snRNAs regardless of its loading position. Non-
responsive mutations could affect the splicing progression
after the exon deﬁnition step and their rescue would require
the complementation with additional splicing factors. Even if
mutations in positions +1 and +2 are not expected to
respond to ExSpeU1 due to the obligate presence of the GT
dinucleotide at the 5′ss, the mechanism that regulates the
rescue efﬁciency of the other mutations is less obvious.
Some positions are known to interact with other splicing
factors in later splicing steps (like the 21 and +5 positions
to U5 snRNA and U6 snRNA, respectively) (45,46). More
studies are necessary to fully address the mechanism and iden-
tify the factors involved in determining the ExSpeU1 respon-
siveness of this type of splicing defects at the donor site.
In conclusion, a single ExSpeU1 appropriately loaded by
complementarity to intronic sequences downstream of the
exon rescues correct splicing impaired by different mutations
and recover the corresponding protein biosynthesis and func-
tion in model gene systems. The functional levels obtained
in the model of Haemophilia B and in SMN2 would produce
in vivo a therapeutic correction of the bleeding defect and of
the SMA phenotype, respectively. ExSpeU1s constitute a
promising novel therapeutic strategy to correct splicing
defects associated to defective exon deﬁnition in several
human disorders.
MATERIALS AND METHODS
Hybrid minigene constructs
pCF exon 12 minigene has been previously described (7) and
exonic and donor splice site mutations were introduced substi-
tuting the AccI-BamHI cassette by polymerase chain reaction
(PCR)-mediated site-directed mutagenesis. To obtain the
pFIX exon 5 minigene, the FIX exon 5 fragment consisting
of the last 314 bp of intron 4, exon 5 (129 bp) and the ﬁrst
278 bp of intron 5 was ampliﬁed from normal genomic
DNA using FIXex5dir and FIXex5rev and cloned into the
pTB NdeI-minigene (7). Polypyrimidine tract and donor
splice site mutations were introduced in pFIXex5 between
the unique PstI and XbaI sites of pFIX exon 5 by
PCR-mediated site-directed mutagenesis. pCI-SMN2 exon 7
was obtained from Dr Adrian Krainer (CSHL, NY, USA).
Modiﬁed and exon-speciﬁc U1 snRNAs were created by re-
placing the sequence between the sites BclI and BglII with oli-
gonucleotides as previously reported (47). Sequences of
oligonucleotides are provided in Supplementary Material,
Table S2. Hybrid minigenes were veriﬁed by the sequence
analysis. Modiﬁed U7 snRNAs (U7 ﬁx10 and U7 cf11) were
created by PCR ampliﬁcation of U7SmOPT vector using
cfsh11U7 and FIXsh10U7 and Sp6 primers. PCR products
were digested with HindIII and StuI and ligated into HindIII/
StuI sites of the U7SmOPT vector and the resulting clones
veriﬁed by the sequence analysis.
The splicing-competent FIX cDNA expression cassette was
synthesized by GeneScript Inc. (Piscataway, NJ, USA) and its
sequence is available upon request. The cassette, inserted in
the pCDNA 3.1+ backbone to make the pBsK-FIX, consists
of a simian virus 40 (SV40) promoter followed by (i) the
human FIX cDNA sequence from exons 1 to 4 and the 5′
portion (544 bp) of intron 4, (ii) a unique NdeI restriction
site, (iii) the last 314 bp of intron 4, exon 5 and the 5′
portion (278 bp) of intron 5, (iv) a NdeI restriction site, (v)
the 3′ end (908 bp) of intron 5 followed by the cDNA se-
quence from exons 6 to 8, and (vi) the SV40 polyadenylation
site. The FIX cDNA fragments were ampliﬁed with high-
ﬁdelity DNA polymerase from the pCMV5-FIX vector. The
NdeI–NdeI cassettes containing the last 314 bp of intron 4,
the exon 5 and the 5′ portion (278 bp) of intron 5 were sub-
cloned into pBsK-FIX to make the mutant variants for inves-
tigation of rescue at the protein level.
Analysis of hybrid minigene expression and SMN splicing
HeLa (human cervical carcinoma), HEK393 and BHK cell
lines were grown in Dulbecco’s modiﬁed Eagle’s medium
with Glutamax I (Gibco) (DMEM with glutamine, sodium
pyruvate, pyridoxine and 4.5 g/l glucose) supplemented with
10% fetal calf serum (Euro Clone) and Antibiotic Antimycotic
(Sigma) according to the manufacturer’s instructions. HeLa
cells grown on six well plates were transfected with Effectene
reagents (Qiagen) according to the manufacturer’s protocol.
0.5 mg of hybrid minigenes were transfected either alone or
with 0.5 mg of wt/mutant U1 snRNA-encoding plasmids.
Total RNA extraction was performed after 24 h of incubation
using TRIreagent (Invitrogen) and reverse transcription reac-
tion was carried out as described (47). alpha2,3 and Bra2
oligonucleotides were used for ampliﬁcation of pCF exon 12
and pFIX exon 5; T7-F2 and E8-75 + 5′R oligonucleotides
for pCI-SMN2. The conditions used for the PCRs were 948C
for 5 min for the initial denaturation, 948C for 45 s, 568Cf o r
45 s, 728C for 45 s for 35 cycles and 728C for 10 min
for the ﬁnal extension. PCR products were resolved on 2%
2396 Human Molecular Genetics, 2012, Vol. 21, No. 11agarose gel electrophoresis. Quantiﬁcation of exon inclusion
was performed using the ImageJ software.
For SMN2 exon 7 analysis, HEK393 cells grown in six wells
were transfected with 2 mg of each ExSpeU1s expression
plasmid with the calcium-phosphate method and RT–PCR
performed with E8-467-R and ﬂuorescently labelled
FAM-E6-F primers. Reactions were incubated at 958C for
3 min followed by 35 cycles at 958C for 30 s, 558C for 30 s
and 728C for 36 s. Ampliﬁed fragments were digested with
DdeI and separated on denaturing capillary electrophoresis
(ABI-3100). Quantiﬁcation of intensity of SMN1 and SMN2
exon 7 inclusion and exclusion bands was performed with
PeakscannerTM software.
Transfection of BHK splicing-competent pBsK-FIX expres-
sion vector and reverse transcription was done as described
(14). PCR reaction was carried out using pBsK-FIXdir and
pBsK-FIXrev oligonucleotides. PCR products were resolved
by 2% agarose gel electrophoresis. Liver RNA (First Choice
Human Total RNA Survey Panel, Ambion, Inc.) was retrotran-
scribed in standard conditions and ampliﬁed with FIX140 and
FIX279 primers.
FIX activity and protein assays
FIX coagulant activity was assessed by the aPTT coagulation
assay (48). FIX antigen levels in the conditioned medium were
evaluated by ELISA (Factor IX antigen, FIX; Afﬁnity Biolo-
gicals, Ancaster, Canada). For western blotting analysis,
26 ml of the conditioned medium were incubated 5 min at
958C and run on 4–12% SDS–PAGE (NuPAGE Bis–Tris
gel, Invitrogen
w, Carlsbad, CA, USA). Proteins were trans-
ferred onto a 0.2 mm nitrocellulose membrane (Whatman
w,
Dassel, Germany), which was blocked over night with PBS
buffer supplemented with 0.1% Tween-20 (PBS-T) and 5%
low fat dry milk (Bio-Rad, Hercules, CA, USA). Membranes
were then incubated for 3 h at room temperature with an anti-
Human F.IX peroxidase conjugated (GAFIX-APHRP; Afﬁnity
Biologicals). The Supersignal
w West Femto reagent (Thermo
Scientiﬁc, Rockford, IL, USA) was exploited for detection.
Plasma derived FIX or rFIX-wt were used to optimize
the assay.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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